Press release
Advanced Ovarian Cancer Pipeline, Clinical Trials, NDA Approvals, and Emerging Drugs 2023 | OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, and oth
Key Takeaways from the Advanced Ovarian Cancer Pipeline Report
• DelveInsight's Advanced Ovarian Cancer Pipeline report depicts a robust space with 60+ active players working to develop 70+ pipeline therapies for Advanced Ovarian Cancer.
• The leading Advanced Ovarian Cancer Companies include OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc, and others.
• Promising Advanced Ovarian Cancer Pipeline Therapies include Bevacizumab, Durvalumab, Olaparib, Niraparib, ZL-2306 (Nirapairb), Fluzoparib, Paclitaxel, BIBF 1120, Karenitecin, Topotecan, and others.
• Advanced Ovarian Cancer companies and academics are working to assess challenges and seek opportunities that could influence Advanced Ovarian Cancer R&D. The Advanced Ovarian Cancer pipeline therapies under development are focused on novel approaches to treat/improve Advanced Ovarian Cancer.
Request a sample and discover the recent breakthroughs happening in the Advanced Ovarian Cancer Pipeline landscape @ Advanced Ovarian Cancer Pipeline Outlook- https://www.delveinsight.com/report-store/advanced-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Advanced Ovarian Cancer Overview
Advanced Ovarian Cancer means that cancer has spread outside the ovaary. It may have spread within the pelvis or abdomen, or further away to other parts of the body such as the lungs. Some women have Advanced Ovarian Cancer when they are first diagnosed, and treatment can cure their cancer. This depends on several factors, including the exact stage of cancer.
Recent Developmental Activities in the Advanced Ovarian Cancer Treatment Landscape
• The US Food and Drug Administration (FDA) granted orphan drug designation to mirvetuximab to treat ovarian cancer; mirvetuximab has also secured this designation in the EU.
• In June 2018, the FDA granted mirvetuximab Fast Track designation to treat patients with a medium to high FRα-positive platinum-resistant ovarian cancer who got administered at least one but no more than three prior systemic treatment regimens for whom single-agent chemotherapy is apt as the following line of therapy.
• Stenoparib (2X-121), a unique, small molecule dual-targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2), was exclusively in-licensed by Allarity Therapeutics (globally) from Eisai and is currently being evaluated in Phase II clinical trial for advanced ovarian cancer.
For further information, refer to the detailed Advanced Ovarian Cancer Drugs Launch, Advanced Ovarian Cancer Developmental Activities, and Advanced Ovarian Cancer News, click here for Advanced Ovarian Cancer Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Advanced Ovarian Cancer Emerging Drugs Analysis
• Oregovomab: OncoQuest
• SC 10914: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
• Stenoparib: Allarity Therapeutics
Advanced Ovarian Cancer Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for advanced ovarian cancer. The companies which have their advanced ovarian cancer drug candidates in the most advanced stage, i.e. phase III include, OncoQuest.
Find out more about the Advanced Ovarian Cancer Pipeline Segmentation, Therapeutics Assessment, and Advanced Ovarian Cancer Emerging Drugs @ Advanced Ovarian Cancer Treatment Landscape- https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Advanced Ovarian Cancer Pipeline Report
• Coverage- Global
• Advanced Ovarian Cancer Companies- OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc, and others.
• Advanced Ovarian Cancer Pipeline Therapies- Bevacizumab, Durvalumab, Olaparib, Niraparib, ZL-2306 (Nirapairb), Fluzoparib, Paclitaxel, BIBF 1120, Karenitecin, Topotecan, and others.
• Advanced Ovarian Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Dive deep into rich insights for drugs for Advanced Ovarian Cancer Pipeline Companies and Therapies, click here @ Advanced Ovarian Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Advanced ovarian cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced ovarian cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Advanced ovarian cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Oregovomab: OncoQuest
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. EP0057: Ellipses Pharma
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. DS-6000a: Daiichi Sankyo Company
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Advanced ovarian cancer Key Companies
23. Advanced ovarian cancer Key Products
24. Advanced ovarian cancer- Unmet Needs
25. Advanced ovarian cancer- Market Drivers and Barriers
26. Advanced ovarian cancer- Future Perspectives and Conclusion
27. Advanced ovarian cancer Analyst Views
28. Advanced ovarian cancer Key Companies
29. Appendix
Got Queries? Find out the related information on advanced ovarian cancer Mergers and acquisitions, advanced ovarian cancer Licensing Activities @ Advanced Ovarian Cancer Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/advanced-ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Ovarian Cancer Pipeline, Clinical Trials, NDA Approvals, and Emerging Drugs 2023 | OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, and oth here
News-ID: 3113461 • Views: …
More Releases from DelveInsight Business Research
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining …
DelveInsight's newly released report, "Geographic Atrophy Pipeline Insight" offers a comprehensive analysis of the evolving Geographic Atrophy (GA) therapeutic landscape, covering 23+ biopharmaceutical companies and 25 investigational drug candidates. The report features in-depth profiles of both clinical- and preclinical-stage assets, along with a detailed therapeutic assessment categorized by product type, development phase, route of administration, and molecular class. It also provides visibility into inactive and discontinued pipeline programs within the…
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
More Releases for Advanced
Advanced Oxidation Technologies Market Size, Share 2021, Impressive Industry Gro …
The Advanced Oxidation Technologies Market is poised to take off in upcoming years hence showing a highly positive outlook through 2020-2028, according to a recently released report. Advanced Oxidation Technologies Market report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices, and value chain analysis of those leaders in the market.
The…
Medical Ceramics Market Analysis and Industry Forecast | Advanced Ceramics Resea …
Allied Market Research published a new report, titled, “Medical Ceramics Market by Type (Aluminum Oxide, Zirconia, and Carbon, Hydroxyapatite, Glass & Bioglass, Zirconia Alumina, Bioresorbable Ceramics, and Piezo Ceramics), by Application (Surgical Instruments, Diagnostic Equipment, Orthopedic Implants, Electronic Implants, Dental Implants, Disposables, and Packaging) – Global Opportunity Analysis and Industry Forecast, 2014 – 2022.” The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five…
Skincell Advanced Reviews – Does Skincell Advanced Really Work?
People want clear, blemish-free skin! However, most people have skin tags, moles, and warts. Some causes are known, while some blemishes are caused without any reason at all. When a regular skincare regimen fails, people turn to costly surgeries and medications. Cleansing and moisturizing might not work well for all. All skin types are not the same, and toners and skincare creams seldom give long-lasting benefits.
Get Skincell Advanced From Its…
Global Advanced Oxidation Technologies Market 2019- 2025 || A-Zone Technologies, …
Synopsis of the Advanced Oxidation Technologies Market:
Latest Report on Advanced Oxidation Technologies Market deliberates the effect of various Factors influencing the market growth and drivers. Its further sheds light on market overview, key manufacturers, strategic adopted by them, size, latest trends and types, revenue, gross margin with regional analysis and forecast to 2025.
Overview of the Advanced Oxidation Technologies Market Report:
Advanced Oxidation Technologies Market report includes knowledge about the market overview…
Global Advanced Materials Market - 3M Company, DowDuPont Inc, Hexcel Corporation …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market - By Product type (Structural Material, Functional Material, Emerging Material) By End User (Building & Construction, Automotive, Aerospace, Defense, Marine, Electrical & Electronics, Healthcare, Oil & Gas and Energy, Others) & Global Region - Market Size, Trends, Share and Forecast 2018-2023” research report will include all the major trends and technologies that…
Global Advanced Materials Market: 3M Company, DowDuPont Inc, Hexcel Corporation, …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market 2017: Market Size, Trends & Opportunity Outlook – Forecast to 2023” research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The…
